Papillary Thyroid Cancer Clinical Trial
Official title:
Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone
Background:
- Thyroid hormone is produced by the thyroid gland, an organ at the base of the neck. Thyroid
hormone controls the body's metabolism and the function of many organs. The thyroid gland
produces two forms of thyroid hormone: T4 and T3. People who have thyroid cancer are treated
with thyroid hormone therapy (synthetic T4, levothyroxine), which at times needs to be
stopped to allow for cancer treatments. At these times, a different form of thyroid hormone
(synthetic T3, liothyronine) is used to reduce the symptoms caused by low levels of thyroid
hormone. Researchers want to know more about how changes in T3 hormone affect the body and
organ function.
Objectives:
- To study how changes in T3 hormone levels affect the body and organ function.
Eligibility:
- Individuals at least 18 years of age who have had most or all of their thyroid removed to
treat thyroid cancer who need to stop taking their regular thyroid hormone dose in
preparation for the treatment of thyroid cancer.
Design:
- The study involves a screening visit and a baseline evaluation. It also includes an
11-day inpatient hospital stay.
- Participants will be screened with a physical exam and medical history. They will also
have blood tests and a neck ultrasound.
- Participants will be evaluated with a physical exam, blood tests, and the following
procedures:
- Glucose tolerance test to measure blood sugar
- Tests of body fat, muscle strength, and calorie burning levels
- Imaging studies of the heart, liver, and thigh muscles
- Quality of life questionnaires
- Food preference and diet questionnaires
- After 4 weeks of treatment with T3 hormone, participants will have an 11-day inpatient
hospital stay to study the effect of thyroid hormone on their metabolism. The stay will
involve the same tests done in the baseline evaluation.
In human adults thyroid hormone action plays a critical role in the modulation of metabolism
and the function of virtually all organ/systems. The specificity of the hormonal action is
ultimately the result of the interaction of the active hormone, triiodothyronine (T3), with
the receptors isoforms and the co-activators and co-repressors specific for the various cells
target of the hormonal action. Circulating and tissue levels of T3 are the result of the
secretion of T3 and its precursor, thyroxine (T4), from the thyroid gland, the peripheral
conversion of T4 into T3, and the degradation of these hormones. This complex system has only
been partially studied in humans and very little is known regarding the kinetics of T3, and
in particular on the correlation between circulating levels of T3 and end-organ target tissue
thyroid hormone action.
The aim of this protocol is to characterize the pharmacokinetics of T3 and its biological
effects at various concentrations in a cohort of thyroidectomized patients undergoing thyroid
hormone replacement therapy withdrawal for the management of thyroid cancer.
Sixteen patients with a clinical indication for thyroid hormone withdrawal in preparation for
131I therapy or 123I diagnostic scan for follow-up and management of differentiated thyroid
cancer will be recruited for this study. After enrollment in the study, the patients baseline
characteristics will be determined during an outpatient visit while receiving levothyroxine
(L-T4) therapy. The L-T4 therapy then will be suspended and substituted with an equivalent
thrice daily liothyronine (L-T3) therapy for one month. Patients will be admitted to the NIH
Clinical Center on the day prior to withdrawal of the T3 therapy until the diagnostic scan or
the administration of radioactive iodine. During the hospitalization for this research
protocol, which is expected to last eleven days, the following studies will be performed:
serial blood sampling for circulating thyroid hormones to obtain pharmacokinetic parameters
of L-T3, lipids, glucose and insulin, resting energy expenditure, echocardiogram, skeletal
muscle strength measurement, cardiac, hepatic and skeletal muscles MRI, and quality of life
and well-being questionnaires. The pharmacokinetic parameters of L-T3 will also be assessed
with the first dose after the diagnostic scan or the administration of radioactive iodine.
The results obtained from this study will help in understanding the effects of thyroid
hormone on metabolism, and may lead to important information on how to optimize the duration
of the thyroid hormone therapy withdrawal for the treatment of thyroid cancer.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03469011 -
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
|
Phase 1 | |
Recruiting |
NCT05752669 -
Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
|
||
Recruiting |
NCT04076514 -
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
|
||
Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
Active, not recruiting |
NCT01723202 -
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
Unknown status |
NCT02140476 -
Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy
|
N/A | |
Recruiting |
NCT06286631 -
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
|
||
Completed |
NCT06325787 -
Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma
|
N/A | |
Terminated |
NCT01974284 -
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
|
N/A | |
Active, not recruiting |
NCT00984191 -
Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid
|
N/A | |
Active, not recruiting |
NCT04731467 -
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
Completed |
NCT02178345 -
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
|
||
Not yet recruiting |
NCT06133374 -
Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
|
||
Completed |
NCT03470259 -
Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
|
Phase 1 | |
Active, not recruiting |
NCT04129411 -
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
|
N/A | |
Recruiting |
NCT03899792 -
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
|
Phase 1/Phase 2 |